Folgen
Hiddo Lambers Heerspink
Hiddo Lambers Heerspink
Bestätigte E-Mail-Adresse bei umcg.nl
Titel
Zitiert von
Zitiert von
Jahr
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ...
New England Journal of Medicine 380 (24), 2295-2306, 2019
36102019
Dapagliflozin in patients with chronic kidney disease
HJL Heerspink, BV Stefánsson, R Correa-Rotter, GM Chertow, T Greene, ...
New England Journal of Medicine 383 (15), 1436-1446, 2020
20192020
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
RT Gansevoort, R Correa-Rotter, BR Hemmelgarn, TH Jafar, ...
The Lancet 382 (9889), 339-352, 2013
19552013
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
CS Fox, K Matsushita, M Woodward, HJG Bilo, J Chalmers, ...
The Lancet 380 (9854), 1662-1673, 2012
10562012
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
HJL Heerspink, BA Perkins, DH Fitchett, M Husain, DZI Cherney
Circulation 134 (10), 752-772, 2016
9722016
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
D De Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, H Christ-Schmidt, ...
New England Journal of Medicine 369 (26), 2492-2503, 2013
8932013
Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes
HJ Lambers Heerspink, D De Zeeuw, L Wie, B Leslie, J List
Diabetes, Obesity and Metabolism 15 (9), 853-862, 2013
7392013
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ...
The Lancet 390 (10105), 1888-1917, 2017
7222017
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease …
BC Astor, K Matsushita, RT Gansevoort, M Van Der Velde, M Woodward, ...
Kidney international 79 (12), 1331-1340, 2011
7202011
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ...
The lancet Diabetes & endocrinology 7 (11), 845-854, 2019
5712019
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
L Tonneijck, MHA Muskiet, MM Smits, EJ Van Bommel, HJL Heerspink, ...
Journal of the American Society of Nephrology 28 (4), 1023-1039, 2017
5402017
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ...
The lancet Diabetes & endocrinology 7 (8), 606-617, 2019
5202019
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
HJL Heerspink, T Ninomiya, S Zoungas, D de Zeeuw, DE Grobbee, ...
The Lancet 373 (9668), 1009-1015, 2009
5052009
Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis
N Tangri, ME Grams, AS Levey, J Coresh, LJ Appel, BC Astor, G Chodick, ...
Jama 315 (2), 164-174, 2016
4302016
Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study
KS Vimaleswaran, A Cavadino, DJ Berry, R Jorde, AK Dieffenbach, C Lu, ...
The lancet Diabetes & endocrinology 2 (9), 719-729, 2014
4032014
Dietary salt intake and mortality in patients with type 2 diabetes
EI Ekinci, S Clarke, MC Thomas, JL Moran, K Cheong, RJ MacIsaac, ...
Diabetes care 34 (3), 703-709, 2011
3572011
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
IH de Boer, ML Caramori, JCN Chan, HJL Heerspink, C Hurst, K Khunti, ...
Kidney international 98 (4), S1-S115, 2020
3552020
Canagliflozin slows progression of renal function decline independently of glycemic effects
HJL Heerspink, M Desai, M Jardine, D Balis, G Meininger, V Perkovic
Journal of the American Society of Nephrology 28 (1), 368-375, 2017
3492017
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ...
The Lancet 393 (10184), 1937-1947, 2019
3382019
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
FA Holtkamp, D De Zeeuw, MC Thomas, ME Cooper, PA De Graeff, ...
Kidney international 80 (3), 282-287, 2011
3102011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20